SITAPHAGE XR 50 500MG 14S
Sitaphage XR 50/500mg Tablets are an oral anti-diabetic medication combining Sitagliptin (50mg) and Metformin (500mg) in an extended-release (XR) formulation. This dual-action medicine helps control high blood sugar levels in adults with Type 2 Diabetes Mellitus. Sitaphage XR enhances insulin secretion, reduces glucose production in the liver, and improves insulin sensitivity—offering steady and long-lasting glycemic control throughout the day.
Uses:
-
Used for the management of Type 2 Diabetes Mellitus.
-
Helps control blood sugar levels in patients not adequately managed by diet and exercise alone.
-
Can be prescribed alone or in combination with other anti-diabetic agents.
-
Reduces the risk of diabetes-related complications such as neuropathy, nephropathy, and cardiovascular issues.
Benefits:
-
Dual Mechanism of Action: Sitagliptin increases insulin release, while Metformin reduces hepatic glucose output.
-
Extended Release Formula: Provides sustained blood sugar control with once-daily dosing.
-
Improves Insulin Sensitivity: Enhances the body’s natural ability to utilize insulin effectively.
-
Supports Weight Maintenance: Does not cause significant weight gain compared to some other diabetes drugs.
-
Lowers Risk of Hypoglycemia: Offers stable glucose control with minimal sugar drops when used correctly.
-
Enhances Quality of Life: Helps maintain steady energy and prevent fatigue due to high sugar levels.
Precautions:
-
Use only under medical supervision.
-
Avoid alcohol consumption during treatment to prevent lactic acidosis.
-
Not recommended for patients with severe kidney or liver impairment.
-
Regularly monitor blood glucose, renal function, and HbA1c levels.
-
Take the tablet with meals to reduce gastrointestinal discomfort.
Side Effects:
-
Common: Nausea, diarrhea, headache, stomach upset, mild hypoglycemia.
-
Rare but serious: Lactic acidosis, allergic reactions, or pancreatitis.
If you experience muscle pain, weakness, or shortness of breath, seek medical attention immediately.